ResTrictOmics has developed a drug that effectively targets aggressive breast cancer tumors that have metastasized. The drug called B49 is a novel peptide that works by reducing tumor size as well as disrupting tumor integrity. Their technology offers patients a live-saving alternative therapy to treat metastasized breast cancers that fail to respond to standard chemotherapy regimens. This unique agent developed by ResTrictOmics has the potential to target 70% of all breast cancers regardless of their subtype classification or chemotherapy-resistance status.

Venture Information
Stage: 
In formation
Industry: 
Therapeutics & Drugs
Technology or Science Area: 
Peptide Therapeutic for metastatic breast cancer targeting B49.
Market: 
Breast cancer patients worldwide.
Company Information
Founders: 
Chioma Okeoma